Adherence and Clinical Effectiveness of a Subcutaneous Insulin Clinical Decision Support Tool in Hospitalized Patients
Main finding · Any euglycemia (70-180 mg/dL)Result — go to the resultOdds ratio 1.30 95% CI 1.04–1.63Authors' conclusion
Use of an EMR-integrated insulin CDS tool was associated with modest glycemic improvements.
Study context
- Population
- Adult inpatients with diabetes and hyperglycemia admitted to 2 academic medical centers, December 1, 2015 to July 30, 2018
- Participants
- 1,750 matched patients
- Exposure
- Use of an electronic medical record (EMR)-embedded subcutaneous insulin clinical decision support (CDS) tool within 24 hours of admission vs matched controls
- Outcome
- Any euglycemia (70-180 mg/dL)
- Follow-up
- Day 2
Methodological detailspropensity score matching with Crump trimming and 1:3 nearest-neighbor matching, 2 academic medical centers
- Propensity score matching with Crump trimming and 1:3 nearest-neighbor matching
- 2 academic medical centers
Main finding
As reported in the abstract
Odds ratio
1.30
95% CI 1.04–1.63
P = 0.02
By group
Tool usevs Matched controls
OR 1.30 (95% CI 1.04–1.63); P = 0.02
Observational data: associations, not effects.
Further findings
Mean glucose, hypoglycemia and hyperglycemia
- Mean glucose levels, hypoglycemia, and hyperglycemia did not differ significantly
Tool uptake on day 1
- Admissions with tool use on day 1
- 662 (12.1%)
- Tool use more common with T1D, CKD or higher baseline glucose; varied by diagnosis and provider type
Adherence: total daily insulin dose within 20% of user-selected dose, among patients for whom the tool was used
- Patients receiving total daily insulin dose within 20% of user-selected dose
- 43.7%
Original publication
Adherence and Clinical Effectiveness of a Subcutaneous Insulin Clinical Decision Support Tool in Hospitalized Patients. J Diabetes Sci Technol. Published 30 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →